NCT01891136: Oral Peanut Immunotherapy for Peanut Allergic Patients
- State
- Completed
- Phase
- Early Phase 1
- People
- 36 taking part
- Started
- Apr 2004
- Primary completion
- Nov 2014
- Arms
- Peanut protein
- Results
- None posted
- 2 Jul 2013: Trial registered
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.
Also known as AR101 powder provided in capsules, Palforzia, Peanut Oral Immunotherapy - Liquid Extract, Peanut protein, Viaskin Peanut patch component peanut protein flour.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.